- Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromabScribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its Nasdaq listing at $14 per share, the midpoint of the ...Endpoints · 4d ago↗ source
- J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B dealJohnson & Johnson and AbbVie, the two pharma giants already in the psychedelic space, also eyed AtaiBeckley, according to a source familiar with the situation, but didn’t make an offer before E…Endpoints · 4d ago↗ source
- Bristol Myers to build ‘powerful’ AI factory; Samsung Biologics bids for peptide maker<figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…